Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Financials Overview

Financials in millions USD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	12,587	12,001	11,020	9,869	8,931	7,574
Revenue Growth	10.23%	8.90%	11.66%	10.51%	17.91%	22.06%
Gross Profit Gross Profit Growth	6,918	6,441	5,859	5,444	5,323	4,732
Operating Income Operating Income Growth	4,910	4,687	4,395	4,308	4,378	3,892
Net Income Net Income Growth	4,405	3,953	-535.6	3,620	3,322	2,342
Earnings Per Share EPS Growth	17.18	15.32	-2.08	13.89	12.82	9.01
EPS Growth	22.12%	-	-	8.35%	42.29%	-12.44%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Trikafta / Kaftrio Trikafta / Kaftrio Growth	10,078	10,313	10,239	8,945	7,687	5,697
Alyftrek Alyftrek Growth	1,625	837.8	-	-	-	-
Casgevy Casgevy Growth	190.5	115.8	10	-	-	-
Journavx Journavx Growth	124.9	59.6	-	-	-	-
Other Collaborative and Royalty Other Collaborative and Royalty Growth	-	30.7	-	-	-	1
Other Other Growth	-	644.7	771.5	924.5	1,244	1,876
Revenue (Total) Revenue (Total) Growth	12,587	12,001	11,020	9,869	8,931	7,574

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	13,642	12,320	11,224	13,716	10,891	7,525
Total Debt Total Debt Growth	1,978	2,036	1,750	808.4	899.7	967.4
Net Cash (Debt) Net Cash Growth	11,664	10,284	9,474	12,908	9,991	6,558
Net Cash Growth	11.07%	8.55%	-26.60%	29.19%	52.36%	14.71%
Net Cash Per Share Net Cash Per Share Growth	45.52	39.86	36.74	49.55	38.56	25.23

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	4,293	3,631	-492.6	3,537	4,130	2,644
Capital Expenditures CapEx Growth	-496.8	-437.6	-297.7	-200.4	-204.7	-235
Free Cash Flow Free Cash Flow Growth	3,796	3,194	-790.3	3,337	3,925	2,409
Free Cash Flow Growth	8.47%	-	-	-14.99%	62.97%	-19.55%

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	54.96%	53.66%	53.17%	55.16%	59.60%	62.48%
Operating Margin	39.01%	39.06%	39.88%	43.65%	49.03%	51.39%
Pretax Margin	41.90%	38.69%	2.25%	44.38%	47.39%	36.05%
Profit Margin	35.00%	32.94%	-4.86%	36.68%	37.20%	30.92%
FCF Margin	30.16%	26.61%	-7.17%	33.81%	43.95%	31.80%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct 5, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	29.38	29.10	-	28.97	22.31	23.84
Forward PE	39.01	22.61	22.66	24.44	18.83	16.42
P/FCF Ratio	33.36	36.02	-	31.42	18.89	23.18
PS Ratio	10.06	9.58	9.41	10.62	8.30	7.37

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Aug 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Oct 2, 2026

Data Sources Report a data error